TPG Biotech
73
32M
37
3.32
15
0.49
21
- Stages of investment
- Areas of investment
Summary
The main department of described VC is located in the San Francisco. The company was established in North America in United States.
Besides them, we counted 1 critical employee of this fund in our database.
Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Biotechnology, Health Diagnostics. Among the most popular portfolio startups of the fund, we may highlight CardioDx, moksha8 Pharmaceuticals, DNAnexus.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The increased amount of exits for fund were in 2014. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The real fund results show that this VC is 11 percentage points more often commits exit comparing to other companies. This TPG Biotech works on 5 percentage points less the average amount of lead investments comparing to the other organizations. The fund is generally included in 2-6 deals every year.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the TPG Biotech, startups are often financed by Kleiner Perkins, TPG Growth, Novo Ventures. The meaningful sponsors for the fund in investment in the same round are Novo Ventures, Kleiner Perkins, OrbiMed. In the next rounds fund is usually obtained by Novo Ventures, Mohr Davidow Ventures, Longitude Capital.
Investments analytics
Analytics
- Total investments
- 73
- Lead investments
- 15
- Exits
- 21
- Rounds per year
- 3.32
- Follow on index
- 0.49
- Investments by industry
- Biotechnology (61)
- Health Care (36)
- Medical (27)
- Pharmaceutical (25)
- Biopharma (13) Show 33 more
- Investments by region
-
- United States (65)
- Philippines (1)
- Canada (3)
- Israel (3)
- Japan (1)
- Peak activity year
- 2017
- Number of Unicorns
- 1
- Number of Decacorns
- 1
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 15
- Avg. valuation at time of investment
- 95M
- Group Appearance index
- 0.92
- Avg. company exit year
- 9
- Avg. multiplicator
- 2.27
- Strategy success index
- 0.60
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Carisma Therapeutics | 21 Sep 2022 | Biotechnology, Health Care, Medical, Life Science, Therapeutics | Late Stage Venture | 30M | United States, Pennsylvania, Philadelphia |
| Kaiima | 12 Jul 2013 | Biotechnology, Cultivation, Horticulture, Other Agriculture, AgTech, Organic Food, Agriculture | Late Stage Venture | North District, Israel, Israel | |
| Phenomic AI | 01 Jan 2017 | Biotechnology, Information Technology, Artificial Intelligence, Machine Learning | Seed | 0 | Canada, Ontario, Old Toronto |
| Trevi Therapeutics | 01 Jan 2019 | Biotechnology, Health Care, Pharmaceutical | Late Stage Venture | 10M | United States, Connecticut |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.